Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome

Maged Costantine

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Pregnant women with antiphospholipid syndrome (APS) are at a high risk of obstetrical complications. The current standard of care, including the use of low-dose aspirin and heparin, has not been shown to prevent preeclampsia or intrauterine growth restriction (IUGR). Due to the similarities in pathophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular disease, statins have been proposed for treating and/or preventing these obstetrical complications. In this issue of the JCI, Lefkou et al. report on a small, observational trial that showed a dramatic improvement in both maternal and fetal/neonatal outcomes in women with APS given pravastatin after the onset of preeclampsia and/or IUGR compared with women in the control group. These results, along with other recent clinical studies, support further evaluation of statins for prevention of preeclampsia in a large-scale randomized clinical trial.

Original languageEnglish (US)
Pages (from-to)2792-2794
Number of pages3
JournalJournal of Clinical Investigation
Volume126
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Pravastatin
Antiphospholipid Syndrome
Pre-Eclampsia
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Growth
Standard of Care
Aspirin
Heparin
Pregnant Women
Cardiovascular Diseases
Randomized Controlled Trials
Mothers
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome. / Costantine, Maged.

In: Journal of Clinical Investigation, Vol. 126, No. 8, 01.08.2016, p. 2792-2794.

Research output: Contribution to journalReview article

@article{9a5e13d98f68492daf6c4e827273a735,
title = "Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome",
abstract = "Pregnant women with antiphospholipid syndrome (APS) are at a high risk of obstetrical complications. The current standard of care, including the use of low-dose aspirin and heparin, has not been shown to prevent preeclampsia or intrauterine growth restriction (IUGR). Due to the similarities in pathophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular disease, statins have been proposed for treating and/or preventing these obstetrical complications. In this issue of the JCI, Lefkou et al. report on a small, observational trial that showed a dramatic improvement in both maternal and fetal/neonatal outcomes in women with APS given pravastatin after the onset of preeclampsia and/or IUGR compared with women in the control group. These results, along with other recent clinical studies, support further evaluation of statins for prevention of preeclampsia in a large-scale randomized clinical trial.",
author = "Maged Costantine",
year = "2016",
month = "8",
day = "1",
doi = "10.1172/JCI89137",
language = "English (US)",
volume = "126",
pages = "2792--2794",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome

AU - Costantine, Maged

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Pregnant women with antiphospholipid syndrome (APS) are at a high risk of obstetrical complications. The current standard of care, including the use of low-dose aspirin and heparin, has not been shown to prevent preeclampsia or intrauterine growth restriction (IUGR). Due to the similarities in pathophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular disease, statins have been proposed for treating and/or preventing these obstetrical complications. In this issue of the JCI, Lefkou et al. report on a small, observational trial that showed a dramatic improvement in both maternal and fetal/neonatal outcomes in women with APS given pravastatin after the onset of preeclampsia and/or IUGR compared with women in the control group. These results, along with other recent clinical studies, support further evaluation of statins for prevention of preeclampsia in a large-scale randomized clinical trial.

AB - Pregnant women with antiphospholipid syndrome (APS) are at a high risk of obstetrical complications. The current standard of care, including the use of low-dose aspirin and heparin, has not been shown to prevent preeclampsia or intrauterine growth restriction (IUGR). Due to the similarities in pathophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular disease, statins have been proposed for treating and/or preventing these obstetrical complications. In this issue of the JCI, Lefkou et al. report on a small, observational trial that showed a dramatic improvement in both maternal and fetal/neonatal outcomes in women with APS given pravastatin after the onset of preeclampsia and/or IUGR compared with women in the control group. These results, along with other recent clinical studies, support further evaluation of statins for prevention of preeclampsia in a large-scale randomized clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84987837117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987837117&partnerID=8YFLogxK

U2 - 10.1172/JCI89137

DO - 10.1172/JCI89137

M3 - Review article

VL - 126

SP - 2792

EP - 2794

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -